Prodrugs: Challenges and Rewards, Parts 1 and 2
Edited by:
Valentino Stella, University of Kansas
Ronald T. Borchardt, University of Kansas
Michael Hageman, Bristol-Myers Squibb
Reza Oliyai, Gilead Sciences, Inc.
Hans Maag, Roche Palo Alto, LLC
Jefferson Tilley, Hoffmann-La Roche, Inc.
Volume 5 of the AAPS Press series, Biotechnology: Pharmaceutical Aspects.
This essential new volume provides a comprehensive overview of prodrugs and will
guide the reader through the current status of the prodrug concept and its many applications.
The wealth of information in this two-part reference work highlights the many successes that
have been achieved in overcoming the formulation and delivery of problematic drugs.
The prodrug concept goes back to the 1950s when early publications of the term described
bioreversible chemical derivatives of medicinal agents used to effect better activity, delivery,
formulation, or targeting to tissues. Later, with the advent of molecular biology and the availability
of pure protein targets, many new chemical entities were found to be effective at the molecular/receptor
level but ineffective as molecules of commercial value. Although difficulties persist with the delivery
of drug delivery and binding, prodrugs continue to be a fertile area of research.
Part 1 is concerned with the design and deliverability of problematic drugs in which the
parent drug is clearly identified and a prodrug solution is sought. Approved and marketed prodrug
examples as well as experimental and research concepts are presented. Part 2 concerns a functional
group approach to prodrugs designed for synthetic medicinal chemists. Also provided are extensive
examples of approved and marketed prodrugs, including 25 case studies which the reader can learn
from and apply to future strategic endeavors in the development of prodrug candidates.
Prodrugs: Challenges and Rewards, Parts 1 and 2 is crucial for the novice as well as the professional
for a complete understanding of the use of prodrugs for the delivery of older but problematic drugs, as well
as to the development of broad-based prodrug technologies for application to new and future drugs.
List Price: $599.00; AAPS Member price: $359
Printable Order Form
Table of Contents, Part 1
Table of Contents, Part 2
|
